Shots:
- TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders
- The focus of the agreement is to develop non-opioid therapies with advancement of mAbs targeting ion channels utilizing TetraExpress technology for the treatment of pain conditions
- TetraExpress technology is an Ab discovery platform for developing biologics targeting ion channel for autoimmune diseases and pain
Click here to read full press release/ article | Ref: Imbrium Therapeutics | Image: MassBio
